In Vivo Real-time Detection of Circulating Melanoma Cells
ConditionMelanoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUniversity of Arkansas
About this trial
The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of melanoma patients in vivo, in real time, and do so at detection limits at least one order of magnitude below the detection limits of currently existing ex vivo methods.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18 to 80 years
Histological documented diagnosis of melanoma
Signed informed consent form approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Review Board (IRB)
Must be able to sit still for 90 minutes
Disqualifiers
Active infection
Current and significant medical or surgical condition as determined by the Investigator
Diagnosis or evidence of organic brain syndrome
Pregnancy or breastfeeding
Trial population
Expect to consent approximately 80 subjects in order to achieve an enrollment goal of 75 subjects at this institution in three cohorts.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
75 Participants
are grouped into 3 trial groupsGroup A: Healthy control subjects
Group B: Advanced-Stage Melanoma
Group C: Early-Stage Melanoma
Trial outcomes
Primary outcomes
1
Number of participants that possess circulating tumor cells.
Time frame
14-21 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov